At a glance
ClinicalIndex Comparison Record- ✓Age 18-50 years and actively seeking treatment for anhedonia
- ✓Clinically significant anhedonia (SHAPS score ≥20)
- ✓Clinically impaired (CGI-S score >3)
- ✓Motivated for anhedonia treatment (referred from clinic or responded to recruitment advertisement)
- ✕Bipolar disorder, mania, schizophrenia spectrum, or other psychotic disorders
- ✕Prior behavioral activation therapy for depression or mindfulness-based treatment
- ✕Intellectual disability, neurocognitive disorders, or dissociative disorders (may impair understanding of cognitive components)
- ✕Feeding and eating disorders (confounding effects on fMRI signal)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Development of a Novel Transdiagnostic Intervention for Anhedonia - R61 Phase
In Brief
A clinical study evaluating Behavioral Activation and Mindfulness Treatment for Anhedonia. Completed, enrolled 57 participants across 1 site.
Detailed Summary
The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging. There is a critical need for a validated treatment that specifically targets anhedonia, and this project will evaluate the effects of this new treatment on anhedonia and will establish how this treatment impacts brain systems that mediate reward processing, clinical symptoms of anhedonia, functional outcomes, and behavioral indices of reward processing. This work will also identify brain targets by which future novel anhedonia treatment may be evaluated.
Study Details
Timeline
Interventions
Treatment will consist of 15 weekly 45-minute sessions.
Treatment will consist of 15 weekly 45-minute sessions.